Tenax Therapeutics (TENX) Enterprise Value (2010 - 2026)
Tenax Therapeutics (TENX) posted quarterly Enterprise Value of -$118.0 million for Q2 2026, down 11.87% year-over-year from -$133.9 million in Q2 2025, and up 0.66% on a QoQ basis from -$118.8 million in Q1 2026.
Tenax Therapeutics (TENX) Enterprise Value (2010 - 2026) Analysis & Trends
Tenax Therapeutics has reported Enterprise Value for 17 years, with the latest figure at -$118.0 million in Q2 2026.
- Enterprise Value for Q2 2026 came in at -$118.0 million, down 11.87% year-over-year; the trailing twelve-month figure through Jun 2026 was -$118.0 million (down 11.87% YoY), and the FY2025 annual result was -$97.6 million, down 2.86% from the prior year.
- Enterprise Value grew to -$118.0 million in Q2 2026, from -$118.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$2.1 million in Q4 2022 and troughed at -$118.8 million in Q1 2026.
- A 5-year average of -$51.7 million and a median of -$13.9 million in 2023 frame the typical range for Enterprise Value.
- The widest annual swing landed in 2022, when Enterprise Value surged 61.96%; it then sank 1023.85% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$2.1 million in 2022, then slumped by 361.02% to -$9.8 million in 2023, then slumped by 868.66% to -$94.9 million in 2024, then fell by 2.86% to -$97.6 million in 2025, then slipped by 20.92% to -$118.0 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$118.0 million in Q2 2026, -$118.8 million in Q1 2026, and -$97.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 2.12 Bn |
| 10 | Tenax Therapeutics | 79.63 Mn | 79.63 Mn | - | -117.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -117.98 Mn |
| Mar 31, 2026 | -118.76 Mn |
| Dec 31, 2025 | -97.57 Mn |
| Sep 30, 2025 | -99.37 Mn |
| Jun 30, 2025 | -105.46 Mn |
| Mar 31, 2025 | -111.45 Mn |
| Dec 31, 2024 | -94.85 Mn |
| Sep 30, 2024 | -98.31 Mn |
| Jun 30, 2024 | -9.38 Mn |
| Mar 31, 2024 | -12.55 Mn |
| Dec 31, 2023 | -9.79 Mn |
| Sep 30, 2023 | -11.14 Mn |
| Jun 30, 2023 | -13.39 Mn |
| Mar 31, 2023 | -14.41 Mn |
| Dec 31, 2022 | -2.12 Mn |
| Sep 30, 2022 | -3.81 Mn |
| Jun 30, 2022 | -7.23 Mn |
| Mar 31, 2022 | -2.87 Mn |
| Dec 31, 2021 | -5.58 Mn |
| Sep 30, 2021 | -8.35 Mn |